What are the chances now of RP 11 not being granted commercial status by FDA ??
i think it must be very low
Given there is no other alternative drug, eyes in trials are improving and no obvious toxicity issues?
At what stage does the market start discounting the (say 90% plus) chances that this first drug generating ~$1 billion in profits around 2027/28?
I presume such results, particularly the lack of tox issues, must also improve the odds on ADOA as well (which is another $1.5 billion p.a.)
$1billion + $1.5 billion = $2.5 billion
which just happens to equate to the current profitability of CSL (capitalised at 146 x the size of PYC)
What are the chances now of RP 11 not being granted commercial...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.025(2.11%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.16 | $45.30K | 38.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4346 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 563 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |